Mark fineman

Company: Glyscend

Job title: Chief Development Officer

Seminars:

Mimicking Metabolic Surgery: A Non-Invasive Oral Therapy for T2D and Obesity 11:30 am

Detailing GLY-200 a first-in-class, orally-administered polymer therapy designed to modulate the mucosal barrier in the GI tract, mimicking the therapeutic effects of gastric bypass surgery without the need for invasive procedures Examining current state of play with ongoing phase 2 trial demonstrating the potential of GLY-200 to deliver disease-modifying benefits for T2D and obesity, offering…Read more

day: Conference Day Two